Table 1 Distribution of 4492 study subjects by selected characteristics at enrolment; diagnosis of hepatocellular carcinoma (HCC) at follow-up; HCC incidence rates and hazard ratios for HCC with 95 % confidence intervals (CI). Naples, 2003–2012

Total

4492

22

63.3 (41.7–96.2)

 Female

2482

10

51.4 (27.6–95.5)

1*

 Male

2010

12

78.5 (44.6–138.3)

1.2 (0.5–2.7)

 < 60

3349

3

11.3 (3.6–35.0)

1*

 60–69

551

9

214.7 (111.7–412.6)

7.5 (1.8–30.8)

 ≥ 70

592

10

252.8 (136.0–469.8)

6.8 (1.6–29.3)

 Anti HCV-negative/HBsAg-negative

4065

2

6.3 (0.8–22.8)

1*

 HCV RNA-negative/HBsAg-positive

95

3

403.3 (83.2–1179)

75.0 (12.3–456.5)

 HCV RNA-positive/HBsAg-negative

239

15

909.3 (509.0–1500)

61.8 (13.3–286.4)

 HCV RNA-positive/HBsAg-positive

4

0

0.0 (0.0–11,938)

0.0 (0.0-∞)

 ≤ 30

3588

9

32.2 (16.8–61.9)

1*

 31–90

784

5

83.9 (34.9–201.6)

1.5 (0.5–4.7)

 > 90

116

8

1006 (503.0–2011)

10.3 (3.6–29.2)

 ≤ 40

3954

8

26.1 (13.1–52.2)

1*

 41–120

490

9

240.1 (125.0–461.5)

4.1 (1.5–11.4)

 > 120

45

5

1598 (665–3840)

10.3 (3.2–33.3)

 ≤ 40

4294

6

18.0 (8.1–40.0)

1*

 41–120

170

11

885.1 (490.2–1598)

9.4 (3.1–28.8)

 > 120

25

5

3539 (1473–8501)

27.4 (7.6–98.0)

 220–700

2253

2

11.4 (1.4–41.1)

1*

 < 220

2203

20

118.4 (72.3–182.8)

50.0 (1.0–100.0)

 < 1.45

3552

1

3.6 (0.5–25.4)

1*

 1.45–3.25

774

5

88.3 (36.8–212.2)

 > 3.25

130

16

1889 (1157–3083)

17.6 (6.2–49.7)